> Detailanzeige

Yoshida, Yukihiko; Watarai, Masato; Fujii, Kenshi; Shimizu, Wataru; Satomi, Kazuhiro; Inden, Yasuya; Murakami, Yoshimasa; Murakami, Masato; Iwasa, Atsushi; Kimura, Masaomi; Yamada, Nobuko; Nakagawa, Tomofumi; Nordaby, Matias; Okumura, Ken

Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial
  • Beteiligte: Yoshida, Yukihiko; Watarai, Masato; Fujii, Kenshi; Shimizu, Wataru; Satomi, Kazuhiro; Inden, Yasuya; Murakami, Yoshimasa; Murakami, Masato; Iwasa, Atsushi; Kimura, Masaomi; Yamada, Nobuko; Nakagawa, Tomofumi; Nordaby, Matias; Okumura, Ken
  • Erschienen: Wiley, 2018
  • Erschienen in: Journal of Arrhythmia
  • Sprache: Englisch
  • DOI: 10.1002/joa3.12024
  • ISSN: 1880-4276; 1883-2148
  • Schlagwörter: Cardiology and Cardiovascular Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>There are limited data on uninterrupted anticoagulation with direct oral anticoagulants during catheter ablation for atrial fibrillation (<jats:styled-content style="fixed-case">AF</jats:styled-content>), particularly in Japan. We planned a subgroup analysis of the <jats:styled-content style="fixed-case">RE‐CIRCUIT</jats:styled-content> study, comparing the use of uninterrupted dabigatran therapy with warfarin therapy during catheter ablation among the Japanese subgroup and with that in the total population.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The <jats:styled-content style="fixed-case">RE‐CIRCUIT</jats:styled-content> study utilized a prospective, randomized, open‐label, blinded endpoint design, and the primary endpoint was the incidence of major bleeding events (<jats:styled-content style="fixed-case">MBE</jats:styled-content>s). Patients were randomized to uninterrupted dabigatran 150 mg twice daily or warfarin. In this study, we analyzed the results in Japanese patients.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 704 enrolled patients in the study, 112 Japanese patients were randomized to dabigatran (n = 65) or warfarin (n = 47). <jats:styled-content style="fixed-case">MBE</jats:styled-content>s were experienced by two patients: one in the dabigatran group (1.6%, cardiac tamponade) and one in the warfarin group (2.2%, groin hematoma) (risk difference vs warfarin −0.6%; 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> −5.8, 4.7). Within the Japanese subgroup, there were no thromboembolic events in both groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>While not designed to show statistical difference between two treatment groups, our results from the Japanese subgroup supported those from the overall population. Furthermore, this study provided clinical information regarding <jats:styled-content style="fixed-case">MBE</jats:styled-content>, especially cardiac tamponade, in Japanese patients.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang